Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
CA 2482669 A1 · Owner: Novartis Ag · Inventors: Sutton, Paul Allen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
New crystal forms of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine also known as nateglinide, may be produced by dissolving nateglinide in any of its forms, including solvates, in an organic solvent to form a solution followed by precipitation of nateglinide from the solution and isolating and , drying the precipitated crystal form of nateglinide. The precipitation of nateglinide may be induced either by cooling the solution or by addition of , another solvent which is miscible with the first solvent but in which nateglinide is only poorly soluble, or by combination of the two. Depending on the solvent a specific crystal form of nateglinide may be obtained e.g. the , R'-type …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 14, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 14, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 14, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.